ZNF26 Inhibitors
Chemical inhibitors of ZNF26 utilize a variety of mechanisms to impede the functional activity of the protein. Palbociclib, by targeting CDK4/6, can lead to decreased phosphorylation of RB1, and subsequently, less transcriptional activation by the E2F family of transcription factors, which includes ZNF26. Similarly, AZD7762's inhibition of CHK1 and CHK2 kinases disrupts the DNA damage response, which can lead to impaired cell cycle arrest and apoptosis, indirectly reducing the functional levels of ZNF26 in damaged cells. Alisertib, which targets Aurora A kinase, can cause an abnormal arrangement of mitotic spindles and mitotic arrest, thereby indirectly preventing cell cycle-dependent transcriptional events that ZNF26 could normally influence.
Further, BI 2536's inhibition of PLK1 can result in mitotic arrest, which may subsequently lead to a reduction in the activity of proteins like ZNF26 that are regulated during the cell cycle. Sunitinib and Sorafenib, through the inhibition of multiple receptor tyrosine kinases and the RAF kinase respectively, can disrupt signaling pathways essential for cell growth and survival, which in turn can lead to a reduced role for ZNF26 in these processes. Gefitinib and Erlotinib, both EGFR inhibitors, can suppress downstream signaling pathways involved in cell proliferation, thus indirectly limiting ZNF26's involvement in these pathways. Lapatinib's dual inhibition of EGFR and HER2/neu further extends this effect, potentially altering the transcriptional regulation in which ZNF26 partakes. Lastly, Crizotinib and Dasatinib target various tyrosine kinases including ALK, MET, ROS1, BCR-ABL, and Src family kinases, which can lead to changes in the cellular signaling landscape and indirectly influence the functional activity of ZNF26 within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib inhibits CDK4/6, which are crucial for cell cycle progression. Inhibition of CDK4/6 can lead to a reduced phosphorylation of RB1, potentially resulting in less transcriptional activation by E2F, including ZNF26. | ||||||
AZD7762 | 860352-01-8 | sc-364423 | 2 mg | $107.00 | ||
AZD7762 inhibits CHK1 and CHK2 kinases, which are involved in DNA damage response. Inhibition of these kinases can lead to impaired cell cycle arrest and apoptosis, indirectly reducing the functional levels of ZNF26 in damaged cells. | ||||||
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
Alisertib targets Aurora A kinase, which is important for cell cycle progression. Its inhibition can lead to abnormal mitotic spindles and mitotic arrest, thereby indirectly inhibiting the function of ZNF26 by preventing cell cycle-dependent transcriptional events. | ||||||
BI 2536 | 755038-02-9 | sc-364431 sc-364431A | 5 mg 50 mg | $148.00 $515.00 | 8 | |
BI 2536 is a potent PLK1 inhibitor. PLK1 is essential for mitotic progression, and its inhibition can lead to mitotic arrest and subsequent dysfunction of cell cycle-regulated proteins like ZNF26. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib inhibits multiple receptor tyrosine kinases, including PDGFR and VEGFR, which are involved in angiogenesis and cell survival signaling pathways. Disruption of these pathways can indirectly inhibit ZNF26 function by affecting cellular growth conditions. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a RAF inhibitor that can lead to the inhibition of the MEK/ERK pathway, which is involved in cell growth and survival. Inhibition of this pathway can indirectly reduce the functional activity of ZNF26 by altering cell signaling dynamics. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib inhibits EGFR tyrosine kinase, which can lead to the suppression of downstream signaling pathways involved in cell proliferation. This can result in an indirect inhibition of ZNF26 function due to reduced proliferation signaling. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib inhibits VEGFR, EGFR, and RET tyrosine kinases, which may indirectly inhibit ZNF26 by disrupting growth factor signaling that could be critical for ZNF26's role in transcriptional regulation associated with cell growth. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib selectively inhibits EGFR tyrosine kinase, which can lead to an indirect inhibition of ZNF26 by altering downstream signaling pathways necessary for the transcriptional activity of proteins involved in cell cycle and proliferation. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib inhibits both EGFR and HER2/neu tyrosine kinases, impacting cell signaling pathways involved in cell growth and survival. This can lead to an indirect inhibition of ZNF26 function by modifying the transcriptional landscape of the cell. | ||||||